Is gnách go bhfuil an réamhaisnéis ar ghalar Alzheimer bocht, ós rud é go bhfuil sé ina riocht dul chun cinn agus degenerative gan leigheas ar eolas.
Athraíonn an ráta dul chun cinn ó dhuine go duine, ach de ghnáth téann an galar níos measa le himeacht ama, rud a fhágann go laghdaíonn sé cumas cognaíoch agus fisiciúil.
De réir mar a théann an galar ar aghaidh, d'fhéadfadh daoine a bheith ag cailliúint cuimhne, deacracht le teanga agus cumarsáid, disorientation, agus athruithe ar an giúmar agus ar iompar.
Faoi dheireadh, b'fhéidir nach mbeidh siad in ann aire a thabhairt dóibh féin agus go mbeidh cúnamh lánaimseartha ag teastáil uathu.
Tá an t-ionchas meán saoil tar éis diagnóis thart ar 8-10 bliain, ach d'fhéadfadh sé seo a bheith éagsúil go forleathan ag brath ar aois an duine aonair, sláinte foriomlán, agus fachtóirí eile.
Cé nach bhfuil aon leigheas ann, is féidir le cóireálacha agus teiripeanna cabhrú le hairíonna a bhainistiú agus cáilíocht saoil a fheabhsú dóibh siúd a bhfuil galar Alzheimer orthu.
Kaldjian LC: Survival versus prognosis in Alzheimer disease. Ann Intern Med. 2004, 141 (7): 575; author reply 575.
Mayeux R, Stern Y, Sano M: Heterogeneity and prognosis in dementia of the Alzheimer type. Bull Clin Neurosci. 1985, 50 (): 7-10.
DeKosky ST, Golde T: Cerebrospinal Biomarkers in Alzheimer Disease-Potential Roles as Markers of Prognosis and Neuroplasticity. JAMA Neurol. 2016, 73 (5): 508-10.
Yaffe K: Treatment of Alzheimer disease and prognosis of dementia: time to translate research to results. JAMA. 2010, 304 (17): 1952-3.
Zhu B, Chen X, Li W, Zhou D: Effect of Alzheimer Disease on Prognosis of Intensive Care Unit (ICU) Patients: A Propensity Score Matching Analysis. Med Sci Monit. 2022, 28 (): e935397.
Malpetti M, Joie R, Rabinovici GD: Tau Beats Amyloid in Predicting Brain Atrophy in Alzheimer Disease: Implications for Prognosis and Clinical Trials. J Nucl Med. 2022, 63 (6): 830-832.
Schaeffer EL, Figueiro M, Gattaz WF: Insights into Alzheimer disease pathogenesis from studies in transgenic animal models. Clinics (Sao Paulo). 2011, 66 Suppl 1 (): 45-54.
Bhagwat N, Pipitone J, Voineskos AN, Chakravarty MM: An artificial neural network model for clinical score prediction in Alzheimer disease using structural neuroimaging measures J Psychiatry Neurosci. 2019, 44 (4): 246-260.
Vermunt L, van Paasen AJL, Teunissen CE, Scheltens P, Visser PJ, Tijms BM: Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. Neurology. 2019, 92 (23): e2699-e2705.
Raji MA, Brady SR: Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. Ann Pharmacother. 2001, 35 (9): 1024-7.
Diúltú freagrachta: leighis
Cuirtear an suíomh gréasáin seo ar fáil chun críocha oideachais agus faisnéise amháin agus ní sholáthraíonn sé comhairle leighis nó seirbhísí gairmiúla.
Níor cheart an t-eolas a chuirtear ar fáil a úsáid chun fadhb sláinte nó galar a dhiagnóisiú nó a chóireáil, agus ba cheart dóibh siúd atá ag lorg comhairle leighis phearsanta dul i gcomhairle le dochtúir ceadúnaithe.
Tabhair faoi deara le do thoil go bhfuil an líonra néarónach a ghineann freagraí ar na ceisteanna, míchruinn go háirithe nuair a bhaineann sé le hábhar uimhriúil. Mar shampla, líon na ndaoine a ndearnadh diagnóis orthu le galar ar leith.
Déan comhairle do dhochtúir nó do sholáthraí sláinte cáilithe eile i gcónaí maidir le riocht leighis. Ná déan neamhaird ar chomhairle leighis ghairmiúil ná déileáil leis mar gheall ar rud éigin a léigh tú ar an suíomh Gréasáin seo. Má cheapann tú go bhféadfadh éigeandáil leighis a bheith agat, glaoigh ar 911 nó téigh go dtí an seomra éigeandála is gaire láithreach. Ní chruthaíonn an suíomh Gréasáin seo ná a úsáid aon chaidreamh dochtúir-othar. Ní dhéanann BioMedLib ná a chuid fostaithe, ná aon ranníocóir leis an suíomh Gréasáin seo aon ionadaíochtaí, sainráite nó intuigthe, maidir leis an bhfaisnéis a sholáthraítear anseo ná a úsáid.
Diúltú freagrachta: cóipchirt
Soláthraíonn an Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (an DMCA) aisíocaíocht do úinéirí cóipchirt a chreideann go sáraíonn ábhar atá le feiceáil ar an Idirlíon a gcearta faoi dhlí cóipchirt na Stát Aontaithe.
Má chreideann tú go dea-chreidimh go sáraíonn aon ábhar nó ábhar a chuirtear ar fáil i ndáil lenár suíomh Gréasáin nó lenár seirbhísí do chóipcheart, féadfaidh tú (nó do ghníomhaire) fógra a sheoladh chugainn ag iarraidh an t-ábhar nó an t-ábhar a bhaint, nó rochtain air a bhac.
Ní mór fógraí a sheoladh i scríbhinn trí ríomhphost (féach an rannán "Contact" le haghaidh seoladh ríomhphoist).
Éilíonn an DMCA go gcuimsíonn do fhógra faoi shárú cóipchirt líomhain an fhaisnéis seo a leanas: (1) cur síos ar an saothar cóipchirt atá ina ábhar don shárú líomhain; (2) cur síos ar an ábhar líomhain atá ag sárú líomhain agus faisnéis leordhóthanach chun ligean dúinn an t-ábhar a aimsiú; (3) faisnéis teagmhála duit, lena n-áirítear do sheoladh, uimhir theileafóin agus seoladh ríomhphoist; (4) ráiteas uait go bhfuil creideamh maith agat nach bhfuil an t-ábhar ar an mbealach a bhfuil gearán á dhéanamh air údaraithe ag úinéir cóipchirt, nó a ghníomhaire, nó ag oibriú aon dlí;
(5) ráiteas uait, arna shíniú faoi phionós perjury, go bhfuil an t-eolas sa fhógra cruinn agus go bhfuil an t-údarás agat na cóipchearta a éilítear a shárú a fhorfheidhmiú;
agus (6) síntiús fisiciúil nó leictreonach úinéir an chóipchirt nó duine údaraithe chun gníomhú thar ceann úinéir an chóipchirt.
D'fhéadfadh moill a bheith ar phróiseáil do ghearán mura gcuirfidh tú an t-eolas thuas go léir san áireamh.
Cumarsáid
Seol ríomhphost dúinn le haon cheist / moladh le do thoil.
What is prognosis of alzheimer?
The prognosis of Alzheimer's disease is generally poor, as it is a progressive and degenerative condition with no known cure.
The rate of progression varies from person to person, but the disease typically worsens over time, leading to a decline in cognitive and physical abilities.
As the disease progresses, individuals may experience memory loss, difficulty with language and communication, disorientation, and changes in mood and behavior.
Eventually, they may become unable to care for themselves and require full-time assistance.
The average life expectancy after diagnosis is around 8-10 years, but this can vary widely depending on the individual's age, overall health, and other factors.
While there is no cure, treatments and therapies can help manage symptoms and improve quality of life for those with Alzheimer's disease.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
Timpeall
Úsáideann BioMedLib ríomhairí uathoibrithe (algorithms foghlama meaisín) chun péirí ceisteanna agus freagraí a ghiniúint.
Tosaímid le 35 milliún foilseachán bithleighis de PubMed/Medline. Chomh maith le leathanaigh ghréasáin de RefinedWeb.
